A preliminary cohort study has revealed that CD14 and CD16 positive (CD14+/CD16+) leukocyte EVs counts in plasma are inversely associated with liver fibrosis severity and show potential to improve risk prediction of severe fibrosis in NAFLD [43]. The gene discussed is CD14; the disease is Hepatic fibrosis.